<table border="grid" id="id_9acb9477-9f90-44b6-953f-b4a27cbef681" width="0.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_0a7763be-d7ff-42d1-a4fd-87198a3d2bdd">Table 3: Incidence of Primary Endpoint Events</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr id="id_51353330-5cd3-4305-a8a1-b46ce79952f4">
<td align="left" valign="top"></td>
<td align="center" colspan="2" valign="top">Incidence</td>
<td align="center" valign="top">Risk Reduction</td>
<td align="center" valign="top">95% C.I.</td>
<td align="center" valign="top">p-Value</td>
</tr>
</thead>
<tbody>
<tr id="id_7511d93c-b04d-4626-986d-281c06a3ed87">
<td align="left" valign="top">
<br/>
</td>
<td align="center" valign="top">Losartan</td>
<td align="center" valign="top">Placebo</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_6b6ba1ff-69b4-40ca-a8b0-651affa86e52">
<td align="left" valign="top">
<br/>Primary Composite Endpoint</td>
<td align="center" valign="top">
<br/>43.5%</td>
<td align="center" valign="top">
<br/>47.1%</td>
<td align="center" valign="top">
<br/>16.1%</td>
<td align="center" valign="top">
<br/>2.3% to 27.9%</td>
<td align="center" valign="top">
<br/>0.022</td>
</tr>
<tr id="id_2eb60f13-480e-4c80-be2f-d6326d615573">
<td align="left" colspan="6" valign="top">
<br/> Doubling of Serum Creatinine, ESRD and Death Occurring as a First Event</td>
</tr>
<tr id="id_32563a14-dc47-4cff-a906-e29054da15ca">
<td align="left" valign="top">    Doubling of Serum Creatinine</td>
<td align="center" valign="top">21.6%</td>
<td align="center" valign="top">26.0%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_d21d6b72-a724-47fe-972c-60098d29b452">
<td align="left" valign="top">    ESRD</td>
<td align="center" valign="top">8.5%</td>
<td align="center" valign="top">8.5%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_a307de1e-ce47-48ec-b6e2-5f4d62842641">
<td align="left" valign="top">    Death</td>
<td align="center" valign="top">13.4%</td>
<td align="center" valign="top">12.6%</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
<td align="center" valign="top">
<br/>
</td>
</tr>
<tr id="id_d301150c-3852-41ce-aaf2-e4a6235d4219">
<td align="left" colspan="6" valign="top">
<br/>Overall Incidence of Doubling of Serum Creatinine, ESRD and Death</td>
</tr>
<tr id="id_979032f7-b9cd-4531-8ae0-9e9dc9fbb83d">
<td align="left" valign="top">   Doubling of Serum Creatinine</td>
<td align="center" valign="top">21.6%</td>
<td align="center" valign="top">26.0%</td>
<td align="center" valign="top">25.3%</td>
<td align="center" valign="top">7.8% to 39.4%</td>
<td align="center" valign="top">0.006</td>
</tr>
<tr id="id_1971143b-0a32-4cab-b12e-795cafce257b">
<td align="left" valign="top">   ESRD</td>
<td align="center" valign="top">19.6%</td>
<td align="center" valign="top">25.5%</td>
<td align="center" valign="top">28.6%</td>
<td align="center" valign="top">11.5% to 42.4%</td>
<td align="center" valign="top">0.002</td>
</tr>
<tr id="id_859ce14f-11be-4709-b522-4022142d6950" stylecode="Botrule">
<td align="left" valign="top">   Death</td>
<td align="center" valign="top">21.0%</td>
<td align="center" valign="top">20.3%</td>
<td align="center" valign="top">-1.7%</td>
<td align="center" valign="top">-26.9% to 18.6%</td>
<td align="center" valign="top">0.884</td>
</tr>
</tbody>
</table>